skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: The role of p53 in treatment responses of lung cancer

Journal Article · · Biochemical and Biophysical Research Communications
 [1];  [2];  [3]
  1. Unit of Medical Radiobiology, Department of Oncology/Pathology, Cancer Center Karolinska R8:00, Karolinska Institutet, Stockholm (Sweden)
  2. Fifth Pneumo-Oncology Unit, Department of Lung Diseases, Forlanini Hospital, Rome (Italy)
  3. Department of Oncology, Karolinska University Hospital-Solna, S-171 76 Stockholm (Sweden)

Resistance to radio- and chemotherapy is a major problem in treatment responses of lung cancer. In this disease, biological markers, that can be predictive of response to treatment for guiding clinical practice, still need to be validated. Radiotherapy and most chemotherapeutic agents directly target DNA and in response to such therapies, p53 functions as a coordinator of the DNA repair process, cell cycle arrest, and apoptosis. In fact, it participates in the main DNA repair systems operative in cells, including NHEJ, HRR, NER, BER, and MMR. Given the high p53 mutation frequency in lung cancer which likely impairs some of the p53-mediated functions, a role of p53 as a predictive marker for treatment responses has been suggested. In this review, we summarize the conflicting results coming from preclinical and clinical studies on the role of p53 as a predictive marker of responses to chemotherapy or radiotherapy in lung cancer.

OSTI ID:
20709227
Journal Information:
Biochemical and Biophysical Research Communications, Vol. 331, Issue 3; Other Information: DOI: 10.1016/j.bbrc.2005.03.192; PII: S0006-291X(05)00715-1; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
Country of Publication:
United States
Language:
English